NeoGenomics, Inc. (NASDAQ:NEO) reported Q2 2017 earnings this Morning, coming in at $0.04 per share, beating Wall Street’s estimates of $0.03 per Share. Revenue for the quarter came in at $66.09 million beating analyst estimates of $62.95 million
Analyst Coverage For NeoGenomics, Inc. (NASDAQ:NEO)
These are 1 Sell Rating, 5 Buy Ratings .
The current consensus rating for NeoGenomics, Inc. (NASDAQ:NEO) is Buy (Score: 2.67) with a consensus target price of $11.00 , a potential (19.96% upside)Recent Insider Trading for NeoGenomics, Inc. (NASDAQ:NEO)
- On 6/22/2017 Jennifer Balliet, VP, sold 10,723 with an average share price of $8.49 per share and the total transaction amounting to $91,038.27.
- On 6/5/2017 Steven A Ross, Insider, sold 70,833 with an average share price of $7.76 per share and the total transaction amounting to $549,664.08.
- On 5/26/2017 Jennifer Balliet, VP, sold 3,334 with an average share price of $7.50 per share and the total transaction amounting to $25,005.00.
- On 3/20/2017 Steven G Brodie, Insider, sold 50,000 with an average share price of $7.93 per share and the total transaction amounting to $396,500.00.
- On 9/23/2016 Maher Albitar, Insider, sold 2,800 with an average share price of $8.40 per share and the total transaction amounting to $23,520.00.
- On 9/20/2016 Maher Albitar, Insider, sold 105,300 with an average share price of $8.20 per share and the total transaction amounting to $863,460.00.
Recent Trading for NeoGenomics, Inc. (NASDAQ:NEO) Shares of NeoGenomics, Inc. closed the previous trading session at 9.16 down -0.01 -0.11% with 193,398 shares trading hands.